Immunic regains compliance with Nasdaq

Immunic (IMUX) announced that it received written notice from Nasdaq on March 27 informing the company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on Nasdaq. According to the notice, Immunic has regained compliance with the minimum bid price requirement, because the closing bid price of the company’s common stock was at $1.00 per share or greater for at least 20 consecutive business days, satisfying the Nasdaq requirement on March 26. As a result, the matter was closed.